BRISBANE, Australia, Jan. 31, 2008--Progen Pharmaceuticals (ASX: PGL, NASDAQ: PGLA) today advises that the first half loss is expected to be in the range of $AUD14.0 million to $AUD14.5 million. This is an increase of approximately 30% over the previous corresponding reporting period loss of $AUD10.95 million.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.